Equities analysts forecast that Profound Medical Corp. (NASDAQ:PROF – Get Rating) will post ($0.45) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Profound Medical’s earnings, with estimates ranging from ($0.52) to ($0.38). Profound Medical posted earnings of ($0.37) per share during the same quarter […]
Profound Medical (NASDAQ:PROF – Get Rating) has been given a $22.00 price objective by research analysts at Raymond James in a report issued on Monday, BayStreet.CA reports. The brokerage presently has an “outperform” rating on the stock. Raymond James’ price target points to a potential upside of 195.30% from the company’s previous close. Several other […]
Wall Street analysts predict that Profound Medical Corp. (NASDAQ:PROF – Get Rating) will report sales of $1.50 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Profound Medical’s earnings. Profound Medical reported sales of $710,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 111.3%. […]
Profound Medical (NASDAQ:PROF – Get Rating) had its target price reduced by Raymond James from $23.00 to $22.00 in a report published on Monday morning, BayStreet.CA reports. Raymond James currently has an outperform rating on the stock. PROF has been the topic of a number of other reports. Zacks Investment Research cut Profound Medical from […]
Profound Medical (NASDAQ:PROF – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.14), MarketWatch Earnings reports. Profound Medical had a negative net margin of 320.56% and a negative return on equity of 30.45%. During the […]